Otezla

Chemical Nameapremilast
Dosage FormTablet (oral; 10 mg, 20 mg, 30 mg)
Drug ClassInhibitors
SystemSkin, Musculoskeletal, Immune
CompanyAmgen
Approval Year2014

Indication

  • For the treatment of adult patients with active psoriatic arthritis.
  • For the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
  • For the treatment of adult patients with oral ulcers associated with Behçet’s disease.
Last updated on 7/19/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Otezla (apremilast) Prescribing Information.2021Amgen Inc., Thousand Oaks, CA
Document TitleYearSource
Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review.2022American Journal of Clinical Dermatology
Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. 2022Journal of Dermatological Treatment
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. 2020Cochrane Database of Systematic Reviews
Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis.2020Orphanet Journal of Rare Diseases
Comparability of European League Against Rheumatology-recommended pharmacological treatments of oral ulcers associated with Behçet’s disease: a systematic literature review of randomized controlled trials.2020Open Access Rheumatology: Research and Reviews
Biologics and small molecules in patients with scalp psoriasis: a systematic review.2020Journal of Dermatological Treatment
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta-analysis.2019Seminars in Arthritis and Rheumatism
Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.2019Rheumatology International
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.2019Journal of the European Academy of Dermatology and Venereology
Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.2018Future Medicine
Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.2018Journal of the American Academy of Dermatology
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.2018Journal of Dermatological Treatment
Biologicals and small molecules in psoriasis: a systematic review of economic evaluations.2018PLoS One
Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.2018Rheumatology International